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The role and fate of B cells in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE) 
are unknown. Using enzyme-linked immunospot assays we now show that B cells reactive to myelin basic protein 
(MBP) accumulate in the CNS of Lewis rats with acute EAE induced by immunization with MBP and adjuvants. We 
also report that B cells are eliminated from the CNS by apoptosis during spontaneous recovery from this disease. 
Apoptotic B cells were identified by flow cytometry of inflammatory cells extracted from the spinal cord and by 
histological sections of the spinal cord using light and electron microscopic immunocytochemistry. B cell apoptosis 
occurred preferentially in the CNS rather than in the peripheral lymphoid organs and was maximal just prior to the 
onset of spontaneous clinical recovery. Three colour flow cytometry indicated that B cells expressing CD95 (Fas) or 
CD95 ligand (CD95L) were highly vulnerable to apoptosis, whereas B cells expressing Bcl-2 were relatively protected 
from apoptosis. We propose that B cells are eliminated from the CNS by the interaction of CD95L and CD95 on the 




Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated inflammatory demyelinating 
disease of the central nervous system (CNS) and is widely studied as an animal model of multiple sclerosis. 
It can be induced in susceptible animals by active immunization with myelin antigens, such as myelin basic 
protein (MBP) and adjuvants or by the passive transfer of T lymphocytes activated by these antigens. The 
inflammatory infiltrate in the CNS in EAE is composed predominantly of CD4+ T lymphocytes and 
macrophages with a smaller proportion of CD8+ T lymphocytes and B lymphocytes[1–3]. 
 
The overall role of B cells in EAE is unclear. Some studies have suggested that intact B cell function is 
required for the induction of EAE by active immunization[4–6] but recent studies in B-celldeficient mice 
have suggested that B cells are not necessary for the development of EAE [7–9]. The role of B cells in the 
CNS in the pathogenesis of EAE is also unclear. They may act as antigen-presenting cells (APC) in the 
CNS and, if myelin-reactive B cells accumulate in the CNS, may locally produce antimyelin antibodies that 
augment demyelination [3]. Another important unanswered question concerns the fate of B cells in the 
CNS during spontaneous recovery from EAE. One possibility is that B cells are eliminated from the CNS 
by apoptosis, as are T cells [10, 11] and macrophages/microglia [12–14]. The present study was undertaken 
to determine whether myelin-reactive B cells accumulate in the CNS in EAE and whether B cells undergo 
apoptosis in the CNS during spontaneous recovery from this disease.  
 
Materials and Methods  
 
Animals  
Female Lewis rats (JC strain), 7–10 weeks old, were obtained from the Central Animal Breeding House of 
the University of Queensland.  
Preparation of inoculum and induction of EAE  
MBP was prepared from guinea-pig brains by the method of Deibler et al. [15]. MBP in 0.9% saline was 
emulsified in an equal volume of incomplete Freund’s adjuvant containing 4 mg/ml Mycobacterium 
butyricum. Under anaesthesia, rats were inoculated in a footpad of one hindfoot with 0.1 ml emulsion. The 
total dose of MBP was 50 µg per rat.  
 
Clinical assessment  
Tail, hindlimb and forelimb weakness were each graded on a scale of 0 (no weakness) to 4 (total paralysis) 
as previously described [16]. The total clinical score was obtained by adding these three scores (maximum 
=12).  
 
Extraction of cells from the spinal cord and the lymphoid organs  
Cells were isolated from the spinal cords of rats perfused with ice-cold saline using previously described 
methods [17]. The entire spinal cord was removed by insufflation, weighed, and a single-cell suspension in 
ice-cold RPMI containing 1% foetal calf serum (FCS) was prepared by passage of the spinal cord through a 
200-mesh stainless steel sieve. The cell suspension was mixed with isotonic Percoll (Percoll: Hank’s 
Balanced Salt Solution 9:1) in a 3:2 ratio (density 1.052) in 50 ml centrifuge tubes and spun for 25 min at 
640×g at 4°C. The cell pellet and the last 9 ml supernatant were resuspended, transferred to a conical 
centrifuge tube, underlaid with 1 ml Ficoll and spun for 20 min at 600×g at 4°C. The cells from the 
interface above the Ficoll were collected, washed and counted. Single-cell suspensions were prepared from 
the draining and non-draining popliteal lymph nodes and the spleen by teasing and passage through a fine 
nylon mesh. Erythrocytes were removed from the spleen cell suspension using Ficoll. Because the present 
study was focused on B lymphocytes, we did not pass the spinal cord inflammatory cells through a nylon 
wool column to enrich for T lymphocytes as we have done in some of our previous studies [17–19].  
 
Antibodies 
 Mouse monoclonal antibodies specific for the αβ T cell receptor (TCRαβ) (R73), CD45RA or A/B 
(CD45RA/B) (OX33; specific for rat B cells [20)] and CD11b/c (OX42; macrophages/microglia) were 
obtained from Dr J Sedgwick (DNAX Research Institute, Palo Alto, CA, USA). Rabbit polyclonal 
antibodies specific for rat CD95 (M-20), CD95 ligand (CD95L, N-20) and Bcl-2 (N-19) were purchased 
from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). The secondary antibodies employed were 
FITC-conjugated swine F(ab2)2 anti-rabbit immunoglobulin (Ig) (Dako, Carpinteria, CA, USA) and PE-
conjugated goat anti-mouse Ig (Dako). Mouse IgG1 (Dako) and normal rabbit serum (Dako) were used as 
control antibodies. The primary and secondary antibodies were diluted in phosphate buffered saline 
(PBS)/azide (1% FCS/1% sodium azide in PBS) plus 10% autologous rat serum.  
 
Labelling of cells and flow cytometric analysis  
Three-colour analysis was used for the simultaneous detection of surface and intracellular antigens and for 
the analysis of DNA content for assessment of apoptosis. Briefly, 105–106 cells were stained for expression 
of cell-surface antigens as previously described [18]. After washing, cells were fixed with 1 ml ice-cold 
0.25% paraformaldehyde in PBS (pH 7.2) overnight at 4°C. They were then washed in PBS and 
permeabilized by gentle resuspension in 1 ml 0.2% Tween 20 in PBS and incubated at 37°C for 15 min. 
Samples were washed, and the intracellular antigen Bcl-2 was labelled in the same manner as for the 
surface antigens. To stain for DNA, the washed samples were then resuspended in an appropriate volume 
(100– 300 µl) of propidium iodide (PI)-staining solution which was freshly prepared by diluting stock 
solution (RNase [5 mg/ml] and PI [250 µg/ml] in 0.1 M PBS containing 0.1 mM EDTA, pH 7.4) with 
PBS/azide. Samples were kept on ice in the dark and analysed within 1 h. Immunofluorescence and DNA 
analysis were performed on a Becton Dickinson (BD) FACScan using CellQuest software, which was 
routinely calibrated using BD CaliBRITE Flow Cytometry Beads and BD FACSComp software. Electronic 
compensation for three-colour analysis ensured unchanged FITC and PE distributions following PI 
labelling of DNA. For each sample, 40,000 events were scored. To avoid detecting nuclear debris, events 
with a low level of PI fluorescence were not collected. For surface and intracellular antigen labelling, the 
Ig-control sample values were subtracted from all other sample values to remove FITC and PE background 
fluorescence. Apoptotic events were defined as those having a lower PI fluorescence than the sharply 
defined G0/G1 peak. 
 
Light and electron microscopic immunocytochemistry  
For immunocytochemistry the rats were perfused through the aorta with 4% paraformaldehyde/0.05% 
glutaraldehyde in 0.1 M PBS (pH 7.4). Segments of the spinal cord were removed and further fixed in the 
above fixative for a total of 3–4 h before being transferred to 0.01 M PBS. Sections (50 µm and 100 µm) 
were cut on a TPI vibratome. For both light and electron microscopic immunocytochemistry, a modified 
protocol of Hsu’s avidin/biotin peroxidase [21] preembedding immunolabelling technique [22] was 
employed as described previously [23] and briefly as follows. After endogenous peroxidase and 
nonspecific binding sites had been blocked with 1% H2O2/0.1% sodium azide solution and with normal 
goat serum (Dako) (1:50 in PBS) respectively, vibratome sections were incubated with the OX33 mouse 
monoclonal antibody against CD45RA/B which was diluted 1:25 in 0.01 M PBS. Sections were washed 
with PBS and then incubated with biotinylated anti-mouse IgG (Vector, Burlingame, CA, USA) diluted to 
1:300 in PBS containing 1% normal rat serum.  
 
After being washed again with PBS, the sections were incubated with an avidin-biotinylated peroxidase 
complex (Vector). The sections were washed with PBS and then reacted with 3,32- diaminobenzidine-
tetrahydrochloride (Sigma, Castle Hill, Australia). Reactions were stopped with PBS, and the sections were 
then washed with saline, re-fixed with modified Karnovsky’s fixative (2% paraformaldehyde/2.5% 
glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.3–7.4) and washed in saline again. The sections 
were then flat-osmicated and flat-embedded [24]. Semithin sections (1 µm) were examined unstained or 
counterstained with toluidine blue. Ultrathin sections were examined with a Jeol JEM-1200 EXII electron 
microscope.  
 
Enzyme-linked immunospot assays  
We used the enzyme-linked immunospot (ELISPOT) assay [25, 26] to determine the frequencies of B cells 
producing antibodies specific for MBP or MBP72–89 (sequence: PQKSQRSQDENPVVHF), the major 
encephalitogenic region of guinea-pig MBP in the Lewis rat (synthesized by the Queensland Institute of 
Medical Research), in the spinal cord, the spleen and the popliteal lymph node draining the inoculation site 
of rats with acute MBP-EAE 13 days after inoculation (day 13). Cells were prepared as described above. 
The culture medium used for this assay was RPMI 1640 supplemented with 216 mg/l l-glutamine (Gibco, 
Rockville, MD, USA), 100 IU penicillin, 100 µg/ml streptomycin, 5×10−5 M 2-mercaptoethanol and 10% 
heat-inactivated FCS. Millipore 96-well filtration plates with mixed cellulose and ester membrane bottoms 
(type HATF, pore size 0.45 µm) were coated with antigen by the addition of 100 µl/well of 500 µg/ml 
MBP or 1 mg/ml MBP72–89 at 4°C overnight. Nonbound antigen was then flicked out and the residual 
binding capacity of the plates was removed by adding 100 µl/well of 5% bovine serum albumin in PBS 
(blocking buffer) for 30 min at 37°C. The blocking solution was then flicked out and the plates washed 
twice with 0.0005% Tween 20/PBS (washing solution), then twice with PBS. One hundred microlitres of 
culture medium was then added to each well and incubated at room temperature, and flicked out 
immediately prior to addition of the cells.  
 
Triplicates of increasing numbers of responder cells prepared from the spinal cord, the spleen and the 
lymph node were incubated in the wells for 120 h in 5% CO2/95% air at 37°C. The cells were then 
discarded by flicking the plates and washing the wells nine times with washing solution and once with 
distilled water. As a positive control, 100 µl of a 1/50 dilution of serum from a rat with EAE (previously 
shown in an enzyme- immunosorbent assay to respond to MBP) was to control wells precoated with 
antigen and no responder cells had been added, and incubated room temperature for 30 min; the serum 
flicked out, and the plates washed thoroughly times with washing solution, then once with water. One 
hundred microlitres of peroxidaseconjugated goat anti-rat IgG (Cappel) diluted in blocking buffer was then 
added to all control wells for 2 h at room temperature. After flicking out the non-bound peroxidase-
conjugated antibody, the wells were again washed four times washing solution, then once with distilled 
Sigma AED Chromogen Kit was used to detect binding. After incubation with the substrate reagent 15 min, 








Statistical analysis  
Percentages of the inflammatory cell populations which were apoptotic were analysed using analysis of 
variance (ANOVA) to compare the cell populations from all organs simultaneously, followed by Student’s 










Course of disease and spinal cord inflammatory cell phenotype  
 
Rats developed neurological signs of EAE nine to 11 days after inoculation (Table 1). The peak of 
neurological signs was on day 13, after which the rats gradually recovered. Pooled spinal cord 
inflammatory cells extracted from groups of three to seven rats were analysed on days 11–15 after 
inoculation. The proportions of the three major inflammatory cell populations in the spinal cord 
(CD45RA/B+ B lymphocytes, TCRαβ + T lymphocytes, and CD11b/c+ macrophages and microglia) are 
shown in Table 1. The highest proportion of B cells (15.4%) was found at the peak of disease on day 13.  
 
Detection of specific antibody-secreting cells by the immunospot assay 
 To determine the frequency of MBP-specific B cells and MBP72–89-specific B cells in the CNS, the spleen 
and the draining popliteal lymph node, we performed ELISPOT assays on cells isolated from rats with EAE 
on day 13. As shown in Table 2, the frequencies of B cells reactive to MBP or to the major 
encephalitogenic epitope MBP72–89 were higher in the CNS than in the peripheral lymphoid organs.  
 
Apoptosis of B cells  
To assess B cell apoptosis, we employed simultaneous flow cytometric analysis of surface antigens and 
DNA content. Figure 1 shows the means and population standard deviations of the percentages of spinal 
cord CD45RA/B+ B cells, TCRαβ + T lymphocytes, and CD11b/c+ macrophages/microglia undergoing 
apoptosis on days 11–15 after inoculation. As shown previously in the CNS for the percentage of all 
inflammatory cells that are apoptotic [17] and the percentage of TCRαβ+ cells that are apoptotic [18], the 
percentage of apoptotic cells within each of the cell populations studied increased until the peak of 
neurological signs on day 13, and then decreased during clinical recovery. On day 13, 10.8% of the B cells 
in the CNS were apoptotic. The presence of apoptotic B cells in the CNS was confirmed histologically by 
light and electron microscopic immunocytochemistry which revealed apoptotic B cells in the parenchyma 
of the spinal cord (Figure 2).  
 
B cell apoptosis occurs preferentially in the CNS rather than in the peripheral lymphoid 
organs  
To determine whether B cell apoptosis occurs in the peripheral lymphoid organs as well as in the CNS, we 
measured by flow cytometry the levels of apoptosis in the total inflammatory, CD45RA/B+, TCRαβ+ and 
CD11b/c+ populations obtained from the CNS, the spleen, and the draining and non-draining popliteal 
lymph nodes. Figure 3 and Table 3 show that B cell apoptosis in EAE mainly occurs in the CNS, as has 






Expression of apoptosis-regulating proteins by B cells  
We have previously shown that CD95+ T cells and CD95L+ T cells are particularly vulnerable to apoptosis 
in the CNS in EAE whereas Bcl-2+ T cells are relatively protected from apoptosis [19]. To determine 
whether apoptosis-regulating proteins play a similar role in B cell apoptosis, we analysed the expression of 
these proteins by CNS-infiltrating CD45RA/B+ cells 13 days after inoculation. The percentage of CD45RA/ 
B+Bcl-2+ cells undergoing apoptosis (10.3±4.7) was much lower than the percentage of CD45RA/B+Bcl-2− 
that B cells expressing Bcl-2 are relatively protected from apoptosis in the CNS in EAE. The percentage of 
CD45RA/B+CD95+ cells that were apoptotic (16.8±16.9) and the percentage of CD45RA/ B+CD95L+ cells 
that were apoptotic (24.3±22.6) were more than twice the percentages of CD45RA/ B+CD95− cells and 
CD45RA/B+CD95L− cells that were apoptotic (7.1±2.6 and 7.6±2.6, respectively). These results indicate 
that the expression of CD95 or CD95L by B cells renders them susceptible to apoptosis. The four groups of 
rats used to obtain these results could be subdivided according to the clinical course of EAE (early onset or 
late onset). Rats with late onset EAE developed neurological signs two days later than the rats with early 
onset EAE, and the mean total clinical score was less in the late onset group (Table 4). Subdividing the rats 
in this way revealed marked differences in the percentages of CD45RA/B+ cells that expressed CD95 or 
CD95L and in the percentages of CD45RA/B+CD95+ cells and CD45RA/B+CD95L+ cells that were 
apoptotic. These results indicate that CNS-infiltrating B cells from rats that are more advanced in the 
course of EAE are more likely to undergo apoptosis through the CD95-mediated pathway. In the spleen and 
draining and non-draining popliteal lymph nodes the B cell expression of CD95 and CD95L was also 




In the present study we have shown by immunospot assays that myelin-reactive B cells accumulate in the 
CNS in acute EAE. We have also shown that B cell apoptosis occurs in the CNS and is maximal just prior 
to the onset of spontaneous clinical recovery from this disease. To our knowledge, B cell apoptosis in the 
target organ of an autoimmune disease has not previously been reported. The B cell apoptosis occurs 
preferentially in the CNS rather than in the peripheral lymphoid organs. Three colour flow cytometry 
indicated that B cells expressing CD95 (Fas) or CD95L were highly vulnerable to apoptosis, whereas B 
cells expressing Bcl-2 were relatively protected from apoptosis. Although CNS-infiltrating B cells have not 
been shown to play a pathogenic role in MBP-induced EAE, their presence in the CNS raises the possibility 
that they may contribute to the pathogenesis, for example by acting as professional APC. Myers et al. [6] 
have shown that anti-MBP antibodies enhance the induction of EAE by passively transferred MBP-specific 
T cells and have proposed that the antibodies increase the presentation of myelin antigens in the CNS to the 
encephalitogenic T cells. If B cells in the CNS do have a pathogenic role, B cell apoptosis may contribute 
to the spontaneous resolution of inflammation in the CNS and clinical recovery.  
 
There are two main mechanisms for the induction of apoptosis in mature B cells. One occurs after hyper-
crosslinking of the B cell antigen receptor (BCR) [28, 29] and does not involve the interaction of CD95 and 
CD95L [30, 31]. The degree of cross-linking of surface Ig (sIg) receptors on mature B cells determines 
whether the B cells proliferate or are deleted; weak sIg cross-linking induces mature B cells to proliferate, 
whereas strong sIg cross-linking by multivalent antigens such as cell membrane antigens eliminates mature 
B cells by apoptosis [32, 33]. BCR-induced apoptosis is dependent on the absence of T cell signals, 
because it can be reversed by interleukin-4 [32], tumour necrosis factor-_ [30] and ligation of CD40, which 
is constitutively expressed on B lymphocytes [34, 35]. B cell and T cell interactions therefore play an 
important role in regulating B cell apoptosis. The second main mechanism of mature B cell apoptosis is 
mediated through CD95, the expression of which is upregulated by the ligation of B cell CD40 by activated 
T cells expressing CD40L [36, 37]. This CD40L-triggered CD95-mediated apoptosis can be overcome by 
BCR antigen recognition [37], but antigen-specific B cells that have been activated for a prolonged period 
can become sensitive to CD95- mediated cell death [38]. The CD95-mediated pathway is postulated to 
result from the ligation of B cell CD95 by T cell CD95L [39].  
 
However, activated B cells express functional CD95L [40] as well as CD95[38], which raises the 
possibility that the interaction of CD95L and CD95 on the same B cell may mediate apoptosis. In the 
present study we have shown that B cells expressing CD95 or CD95L in the CNS are much more 
vulnerable to apoptosis than B cells not expressing these proteins. This strongly suggests that B cell 
apoptosis in the CNS in EAE is mediated by the interaction of CD95L and CD95 on the same B cell, just as 
the interaction of CD95L and CD95 on the same T cell appears to lead to T cell apoptosis in the CNS [19]. 
We also found that Bcl-2 expression appears to protect against B cell apoptosis in the CNS. As Bcl-2 can 
inhibit CD95-mediated apoptosis in some cell types [41], we hypothesize that CD95-mediated apoptosis is 
occurring in CNS B cells that are expressing low levels of Bcl-2. Low Bcl-2 expression may result from 
cytokine withdrawal following activation-induced apoptosis of autoreactive T cells. This CD95-mediated 
mechanism could be responsible for the deletion of both autoreactive and non-autoreactive B cells. It is also 
possible that some B cells are being deleted in the CNS by non-CD95-dependent mechanisms, for example 
BCR hyper-crosslinking [28, 29], or by the action of endogenous glucocorticosteroids [42] which are 
produced during recovery from acute EAE [43]. In conclusion, we have reported the new finding of B cell 
apoptosis in the CNS in EAE and suggested that it might contribute to the spontaneous resolution of CNS 
inflammation and clinical recovery in acute EAE. A detailed understanding of the process of inflammatory 
cell elimination in the target organ and how it might fail in chronic autoimmune disorders may lead to a 
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